Alamar Biosciences is expected to report Q3 2026 revenue of $30.19 million and a loss of $0.22 per share, with its current stock price of $30.60 trading near the average analyst target of $31.80.
Investors are primarily focused on the growth of the "consumables flywheel," which reached 53% of total revenue in the previous quarter and is a critical driver for long-term scalability.
The company recently raised its full-year 2026 revenue guidance to a range of $116 million to $120 million following the successful IPO and rapid adoption of its NULISA proteomics platform.
Analysts are monitoring whether the company can maintain its target of 100+ instrument placements for the year while managing high operating expenses associated with commercial expansion and clinical validation studies.